When patients with HR+ advanced breast cancer progress despite nonsteroidal aromatase inhibitors, the current treatment paradigm includes EXE followed by tamoxifen, toremifene, or fulvestrant [4]. This evidence concerns the gene CYP19A1 and breast carcinoma.